Reduced recurrence of prostate cancer with novel autologous cancer vaccine (FK- PC101) post-prostatectomy: long-term results from a single-center phase 1/2 study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.An investigational prostate cancer vaccine, FK-PC101, shows promise in reducing PSA recurrence in high-risk patients after surgery. Further trials are recommended to confirm its efficacy and safety profile.
Area Of Science
- Oncology
- Immunotherapy
- Urologic Oncology
Background
- Prostate cancer significantly contributes to male cancer mortality.
- High-risk patients with biochemical recurrence (BCR) post-radical prostatectomy (RP) have limited treatment options.
- Current adjuvant therapies like radiotherapy, chemotherapy, and androgen deprivation therapy (ADT) offer minimal benefit.
Purpose Of The Study
- To evaluate the safety, feasibility, and efficacy of FK-PC101, an autologous immunomodulated tumor cell vaccine.
- To assess FK-PC101's impact on biochemical recurrence-free survival (BRFS) and overall survival (OS) in high-risk post-RP patients.
Main Methods
- Retrospective analysis of data from the FK002-2001 phase 1/2 trial.
- Inclusion of 62 high-risk post-RP patients: 23 in the vaccine group and 39 controls.
- Primary endpoints: safety and feasibility; Secondary endpoints: BRFS and OS.
Main Results
- FK-PC101 was well-tolerated, with predominantly grade 1-2 local adverse events.
- Significantly lower prostate-specific antigen (PSA) recurrence at 4 years in the vaccine group (11.8%) versus controls (36.8%; P=0.0453).
- No significant difference in OS between groups; increased erectile dysfunction observed in the vaccine group (P=0.047).
Conclusions
- FK-PC101 demonstrates safety and potential clinical benefit in reducing PSA recurrence post-RP for high-risk prostate cancer.
- Findings support further investigation in a randomized phase 2 trial to confirm efficacy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.